Is TG Therapeutics Stock a Good Investment?

TG Therapeutics Investment Advice

  TGTX
To provide specific investment advice or recommendations on TG Therapeutics stock, we recommend investors consider the following general factors when evaluating TG Therapeutics. This will help you to make an informed decision on whether to include TG Therapeutics in one of your diversified portfolios:
  • Examine TG Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research TG Therapeutics' leadership team and their track record. Good management can help TG Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact TG Therapeutics' business and its evolving consumer preferences.
  • Compare TG Therapeutics' performance and market position to its competitors. Analyze how TG Therapeutics is positioned in terms of product offerings, innovation, and market share.
  • Check if TG Therapeutics pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about TG Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in TG Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if TG Therapeutics is a good investment.
 
Sell
 
Buy
Strong Hold
Our advice module complements current analysts and expert consensus on TG Therapeutics. It analyzes the company potential to grow using all fundamental, technical, and market related data available at this moment. To make sure TG Therapeutics is not overpriced, please validate all TG Therapeutics fundamentals, including its shares owned by insiders, total debt, retained earnings, as well as the relationship between the revenue and earnings per share . Given that TG Therapeutics has a number of shares shorted of 25.99 M, we advise you to double-check TG Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself this quarter and beyond given your latest risk tolerance and investing horizon.

Market Performance

OKDetails

Volatility

Not too volatileDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Very LowDetails

Economic Sensitivity

Follows the market closelyDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Possible ManipulatorDetails

Examine TG Therapeutics Stock

Researching TG Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 66.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.1. TG Therapeutics had not issued any dividends in recent years. The entity had 100:5625 split on the 30th of April 2012.
To determine if TG Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding TG Therapeutics' research are outlined below:
TG Therapeutics had very high historical volatility over the last 90 days
TG Therapeutics currently holds about 195.71 M in cash with (31.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45.
TG Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 66.0% of the company shares are owned by institutional investors
Latest headline from simplywall.st: Have Insiders Sold TG Therapeutics Shares Recently
TG Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in TG Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to TG Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact TG Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises TG Therapeutics' investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-04
2024-09-300.030.02-0.0133 
2014-03-05
2013-12-31-0.17-0.19-0.0211 
2013-05-14
2013-03-31-0.15-0.17-0.0213 
2024-05-01
2024-03-31-0.04-0.07-0.0375 
2012-11-08
2012-09-30-0.12-0.16-0.0433 
2017-11-08
2017-09-30-0.43-0.48-0.0511 
2016-08-08
2016-06-30-0.28-0.33-0.0517 
2016-03-07
2015-12-31-0.32-0.37-0.0515 

Know TG Therapeutics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as TG Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TG Therapeutics backward and forwards among themselves. TG Therapeutics' institutional investor refers to the entity that pools money to purchase TG Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Deep Track Capital, Lp2024-09-30
1.7 M
Bank Of America Corp2024-09-30
1.7 M
Hood River Capital Management Llc2024-09-30
1.6 M
Northern Trust Corp2024-09-30
1.4 M
Charles Schwab Investment Management Inc2024-09-30
1.2 M
Fmr Inc2024-09-30
1.2 M
683 Capital Management Llc2024-09-30
1.1 M
Two Sigma Investments Llc2024-09-30
1.1 M
Amvescap Plc.2024-09-30
918.8 K
Blackrock Inc2024-09-30
22 M
Vanguard Group Inc2024-09-30
15.4 M
Note, although TG Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

TG Therapeutics' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.6 B.

Market Cap

2.29 Billion

TG Therapeutics' profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets 0.03  0.04 
Return On Capital Employed 0.09  0.07 
Return On Assets 0.03  0.04 
Return On Equity 0.07  0.07 
The company has Profit Margin (PM) of (0.05) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.
Determining TG Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if TG Therapeutics is a good buy. For example, gross profit margin measures TG Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of TG Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in TG Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TG Therapeutics. Check TG Therapeutics' Beneish M Score to see the likelihood of TG Therapeutics' management manipulating its earnings.

Evaluate TG Therapeutics' management efficiency

At this time, TG Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2025, whereas Return On Capital Employed is likely to drop 0.07 in 2025. At this time, TG Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 383.9 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 7.6 M in 2025. TG Therapeutics' management efficiency ratios could be used to measure how well TG Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for Next Year
Book Value Per Share 1.30  1.24 
Tangible Book Value Per Share 1.29  1.23 
Enterprise Value Over EBITDA 84.22  88.43 
Price Book Value Ratio 13.60  14.28 
Enterprise Value Multiple 84.22  88.43 
Price Fair Value 13.60  14.28 
Enterprise Value2.2 B2.3 B
Understanding the operational decisions made by TG Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta
2.193

Basic technical analysis of TGTX Stock

As of the 18th of January 2025, TG Therapeutics owns the Risk Adjusted Performance of 0.0994, downside deviation of 4.26, and Mean Deviation of 3.38. In connection with fundamental indicators, the technical analysis model makes it possible for you to check timely technical drivers of TG Therapeutics, as well as the relationship between them.

TG Therapeutics' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TG Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on TG Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TG Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

TG Therapeutics' Outstanding Corporate Bonds

TG Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. TG Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most TGTX bonds can be classified according to their maturity, which is the date when TG Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand TG Therapeutics' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing TG Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider TG Therapeutics' intraday indicators

TG Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of TG Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

TG Therapeutics Corporate Filings

8K
14th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8th of January 2025
Other Reports
ViewVerify
F4
7th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
TG Therapeutics time-series forecasting models is one of many TG Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary TG Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

TGTX Stock media impact

Far too much social signal, news, headlines, and media speculation about TG Therapeutics that are available to investors today. That information is available publicly through TGTX media outlets and privately through word of mouth or via TGTX internal channels. However, regardless of the origin, that massive amount of TGTX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of TG Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of TG Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to TG Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive TG Therapeutics alpha.

TG Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards TG Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

TG Therapeutics Corporate Executives

Elected by the shareholders, the TG Therapeutics' board of directors comprises two types of representatives: TG Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TGTX. The board's role is to monitor TG Therapeutics' management team and ensure that shareholders' interests are well served. TG Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TG Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sean CPACorporate CFOProfile

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.